Technologies Enabling Next Generation Vaccine Development
Vaccine Delivery platforms: This section covers various nanoparticle-based vaccine delivery platforms such as nanoparticles of biological (self-assembling proteins) and non-biological origin ( inorganic and polymeric). The biological nanoparticles subsection overlaps with virus-like particles that has been separately addressed.
Virus-Like Particles: Virus-Like Particles are biological nanoparticles having size of around 20-100 nm. Due to the repetitive nature, viral capsid proteins have tendency to self-assemble. Lack of genetic material makes them non-replicative and hence safe vaccines. Therefore, VLPs are gaining a lot of attractions from vaccine development point of view.
Bacterial and fungal vaccines: This part discusses upcoming vaccines which can protect against multiple bacterial and fungal infections, toxoid vaccines, neutralizing antibodies and new technologies like carbohydrate-conjugate vaccines, surface antigen vaccines etc.
Synthetic vaccines: The segment of synthetic vaccines talks about the short, long and synthetic peptide vaccines against viral and bacterial diseases, innovative T cell stimulating immunogens and fusion proteins.
Viral vector-based vaccines: It covers genetically modified viral vectors which are engineered to make replication incompetent by deletion of essential genes or highly attenuated viral vectors that lack pathogenic genes.
Adjuvant technology: Unique lipid-based adjuvants, oil-in-water adjuvants, plant-derived adjuvants, synthetic and immune-cell-receptor based adjuvants as well as virosomes (derived from viral proteins) are reviewed here.
Vaccine synthesis, formulation and delivery platforms: This section partially overlaps with virus-based vaccine delivery platforms like virosomes, synthetic and modified-viral platforms, cell-free protein synthesis and gene delivery methods and proprietary cell lines used for vaccine production.
- Executive Summary
- Research Scope: Vaccine Technologies Under Development Phase
- Analysis Framework: Frost & Sullivan Core Value
- Research Methodology: Five Steps Toward Success
- Key Findings of Global Vaccine Technology Development
- Technology Snapshot
- Research Scope: Current Status and Challenges of Vaccine Development
- Technologies Transforming Next-generation Vaccines
- Nanoparticles as Novel Vaccine Delivery Platforms
- Nanoparticles Enable Efficient and Safe Vaccine Delivery
- Self-assembling Nanoparticles of Biological Origin
- Polymeric and Inorganic Nanoparticles for Vaccine Delivery
- Virus-like Particles Are Self-assembling Virus Capsid Proteins Without The Genetic Material
- Virus-like Particles Mimic The Real Viral Infection
- Landscape of VLP-based Vaccines, Global, 2019
- Influenza Shares A Major Portion of VLP-based Vaccines
- Multiple Adaptations of VLP Technology for Vaccine Development
- Plant Leaves Producing A Wide Variety of VLPs
- Bacterial and Fungal Vaccines
- Emerging Technologies for Bacterial and Fungal Vaccines
- Emerging Bacterial and Fungal Vaccines, Global, 2019
- New Strategies for Bacterial and Fungal Vaccines
- Novel Vaccines & Therapeutics for Emerging Infectious Diseases
- Multi-protein Complex-based Bacterial Vaccines
- Carbohydrates-based or Conjugate Vaccines
- Synthetic Vaccines
- Development Status of Synthetic Vaccines, Global, 2019
- Peptides-based Vaccine Technologies
- Genetically Modified Vaccines for HIV and Streptococci
- Viral Vector-based Vaccines
- Overview of Viral Vector-based Vaccines
- Summary of Developing Viral Vector Vaccine Technology, Global, 2019
- Diverse Replication-incompetent Viral Vaccines
- Replication-incompetent Viruses with Nasal Spray Formulation
- Live Attenuated Influenza Vaccines with Nasal Formulation
- Viral Vector Vaccines for Serious Human Diseases
- Versatile Viral Vector Vaccine Platforms
- Adjuvant Technology
- Novel Lipid Formulations as Adjuvant
- Oil-in-water Nanoemulsion and Saponin-based Adjuvants
- Toll-like Receptor-based Adjuvants
- Vaccine Synthesis, Formulation, and Delivery Platforms
- Synopsis of Vaccine Synthesis, Formulation Delivery Platforms
- Cell-free and Cell-based Vaccine Synthesis Platforms
- Diverse Vaccine Formulation Technologies
- Needle-less Solid Dose Vaccine Delivery Formulation and Device
- Gold Nanoparticles and Applications in Vaccine Delivery
- Nanopatch, Recombinant Protein and Lipid-based Carriers
- Growth Opportunities and Companies to Action
- Growth Opportunity 1: Influenza Vaccines
- Growth Opportunity 2: Vaccines for Vector Borne Viral Diseases
- Growth Opportunity 3: Vaccine Delivery Technologies
- Strategic Imperatives for Success and Growth
- Key Industry Influencers